UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section
13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
(Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code:
(
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities pursuant to Section 12(b) of the Act:
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 | Other Events. |
On April 1, 2024, Outlook Therapeutics, Inc. (the “Company”) received written notice (the “Compliance Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on The Nasdaq Capital Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from March 14, 2024 to March 28, 2024, the closing bid price of the Company’s common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter was now closed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Outlook Therapeutics, Inc. | ||
Date: April 2, 2024 | By: | /s/ Lawrence A. Kenyon |
Lawrence A. Kenyon | ||
Chief Financial Officer |
Cover |
Apr. 01, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Apr. 01, 2024 |
Entity File Number | 001-37759 |
Entity Registrant Name | Outlook Therapeutics, Inc. |
Entity Central Index Key | 0001649989 |
Entity Tax Identification Number | 38-3982704 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 485 Route 1 South |
Entity Address, Address Line Two | Building F |
Entity Address, Address Line Three | Suite 320 |
Entity Address, City or Town | Iselin |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 08830 |
City Area Code | 609 |
Local Phone Number | 619-3990 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | OTLK |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
-8?20$3;
M8T.P6BP^0"X99K>]9!:G
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end